Nonsteroidal Anti- Inflammatory Agent
Management of Acute Gouty Arthritis
Zoryve launches in the U.S. for treatment of seborrheic dermatitis
Arcutis has officially launched sales for Zoryve topical foam 0.3% in the U.S. for the treatment of seborrheic dermatitis in individuals aged 9 years and older, according to a press release.
Gout clinical practice guidelines disagree on when to start urate lowering therapy
Clinical practice guidelines for gout disagree on when urate lowering therapy should begin and how long it should last, as well as on the use of vitamin C, pegloticase, fenofibrate and losartan, according to data published in BMC Rheumatology.
Pharmacology Consult: Updates on management of acute and recurrent pericarditis
Acute and recurrent pericarditis are the most common pericardial syndromes and represent an etiology of chest pain that is associated with substantial morbidity, decreased quality of life and, rarely, mortality.
Clinicians provide recommendations for sick day medication guidance
A group of clinicians provided 46 consensus recommendations for sick day medication guidance for patients with diabetes, kidney or cardiovascular disease, according to data published in the American Journal of Kidney Diseases.
Opioids nearly double risk for venous thromboembolism vs. NSAIDs in rheumatoid arthritis
PHILADELPHIA — Opioid use in rheumatoid arthritis demonstrates a nearly two-fold increased risk for venous thromboembolism vs. NSAIDs, according to data presented at ACR Convergence 2022.
An evidence-based look at the CV safety of NSAIDs
There has been significant controversy in the past several years surrounding the safe use of nonsteroidal anti-inflammatory drugs in patients with or at risk for CVD.